secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001651308-25-000066
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

USPTO invalidates all challenged claims of Pharmacyclics patent in BeiGene's BRUKINSA® PGR
--------------------------------------------------------------------------------

- USPTO Final Written Decision invalidates all claims of Pharmacyclics' U.S. Patent No. 11,672,803 challenged by BeiGene in post-grant review.
- Patent is part of infringement lawsuit against BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) filed by Pharmacyclics in 2023.
- BeiGene filed PGR petition on November 1, 2023; USPTO decision is appealable by Pharmacyclics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000066/0001651308-25-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000066/bgne-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001651308-25-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer